Concepedia

David Friedland

DF

34

Publications

1.9K

Citations

23

H-Index

1995

Active since

Affiliations

UPMC Hillman Cancer Center(Current)

University of Pittsburgh

University of Pittsburgh Medical Center

Duke Medical Center

Carlow University

David Friedland is an author at UPMC Hillman Cancer Center specializing in medicine, oncology, and cancer therapeutics.

Top concepts

Publications per year

1995–2023

34

Publications

34

CANVAS 2: the second Phase III, randomized, double-blind study evaluating ceftaroline fosamil for the treatment of patients with complicated skin and skin structure infections

Mark H. Wilcox, G. Ralph Corey, George H. Talbot et al. · Journal of Antimicrobial Chemotherapy · 2010 · 212 citations

CANVAS 1: the first Phase III, randomized, double-blind study evaluating ceftaroline fosamil for the treatment of patients with complicated skin and skin structure infections

G. Ralph Corey, Mark H. Wilcox, George H. Talbot et al. · Journal of Antimicrobial Chemotherapy · 2010 · 160 citations

A phase II trial of docetaxel (Taxotere) in hormone-refractory prostate cancer: correlation of antitumor effect to phosphorylation of Bcl-2.

David Friedland, Jonathan E. Cohen, Rachel Miller et al. · PubMed · 1999 · 153 citations

Results of a Single Institution Experience with Dose-Escalated Chemoradiation for Locally Advanced Unresectable Non-Small Cell Lung Cancer

Mark E. Bernard, Scott Glaser, Beant S. Gill et al. · Frontiers in Oncology · 2017 · 141 citations · Full text

Phase II Study of Everolimus (RAD001) in Previously Treated Small Cell Lung Cancer

Ahmad A. Tarhini, Αthanasios Kotsakis, William E. Gooding et al. · Clinical Cancer Research · 2010 · 130 citations

Rows per page

1–5 of 34